Shopping Cart
Remove All
Your shopping cart is currently empty
Ubamatamab
😃Good
Catalog No. T76967Cas No. 2305629-50-7
Ubamatamab represents a highly specialized bispecific T-cell engaging antibody specifically engineered to bridge the structural gap between MUC16-expressing malignant ovarian cancer cells and cytotoxic T-lymphocytes by maintaining stable engagement with the CD3 receptor complex to evaluate the induction of tumor-specific immune responses across various preclinical experimental models in specialized oncology research environments.
Ubamatamab
Ubamatamab
😃Good
Catalog No. T76967Cas No. 2305629-50-7
Ubamatamab represents a highly specialized bispecific T-cell engaging antibody specifically engineered to bridge the structural gap between MUC16-expressing malignant ovarian cancer cells and cytotoxic T-lymphocytes by maintaining stable engagement with the CD3 receptor complex to evaluate the induction of tumor-specific immune responses across various preclinical experimental models in specialized oncology research environments.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $790 | - | In Stock | |
| 5 mg | $2,280 | - | In Stock | |
| 10 mg | $3,600 | 2-4 weeks | 2-4 weeks |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:>95% (SDS-PAGE); 98.42% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ubamatamab represents a highly specialized bispecific T-cell engaging antibody specifically engineered to bridge the structural gap between MUC16-expressing malignant ovarian cancer cells and cytotoxic T-lymphocytes by maintaining stable engagement with the CD3 receptor complex to evaluate the induction of tumor-specific immune responses across various preclinical experimental models in specialized oncology research environments. |
| In vitro | In T-cell engagement assays using ovarian cancer cell lines, Ubamatamab (REGN4018) facilitated cytolytic synapse formation with MUC16-expressing tumor cells, leading to target cell lysis [1]. |
| In vivo | In MUC16-expressing human tumor xenograft models, systemic administration of Ubamatamab (REGN4018) resulted in significant tumor regression and durable antitumor immunity [1]. |
| Reactivity | Human |
| Verified Activity | OVCAR-3 cells at 1×10^5 cells/well can bind Ubamatamab. The EC50 is 0.421 nM.
huCD3e-Jurkat cells at 1×10^5 cells/well can bind Ubamatamab. The EC50 is 15.06 nM.   |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CD3E & MUC16 |
| Molecular Weight | 144.64 kDa |
| Cas No. | 2305629-50-7 |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | Lyophilized powder: -20~-80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Ubamatamab | purchase Ubamatamab | Ubamatamab cost | order Ubamatamab | Ubamatamab in vivo | Ubamatamab in vitro | Ubamatamab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.